Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Receivables - Other (2017 - 2023)

BeOne Medicines (BEIGF) has disclosed Receivables - Other for 7 consecutive years, with $1.7 million as the latest value for Q4 2023.

  • Quarterly Receivables - Other fell 42.91% to $1.7 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2023, down 42.91% year-over-year, with the annual reading at $1.7 million for FY2023, 42.91% down from the prior year.
  • Receivables - Other for Q4 2023 was $1.7 million at BeOne Medicines, up from $1.6 million in the prior quarter.
  • The five-year high for Receivables - Other was $7.2 million in Q3 2021, with the low at $1.3 million in Q1 2023.
  • Average Receivables - Other over 5 years is $3.9 million, with a median of $3.2 million recorded in 2019.
  • The sharpest move saw Receivables - Other soared 242.6% in 2020, then crashed 74.81% in 2023.
  • Over 5 years, Receivables - Other stood at $1.9 million in 2019, then skyrocketed by 242.6% to $6.6 million in 2020, then decreased by 23.67% to $5.1 million in 2021, then plummeted by 39.85% to $3.0 million in 2022, then tumbled by 42.91% to $1.7 million in 2023.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $1.7 million, $1.6 million, and $2.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.